Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
15
XWEL Quote, Financials, Valuation and Earnings
Last price:
$0.45
Seasonality move
:
-5.03%
Day range:
$0.43 - $0.51
52-week range:
$0.43 - $1.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.08x
P/B ratio:
0.66x
Volume:
136.1K
Avg. volume:
30.5K
1-year change:
-69.48%
Market cap:
$2.7M
Revenue:
$33.9M
EPS (TTM):
-$3.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.23 | -80.82% | -75.61% | $7.00 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$131.7M | $0.39 | 11.04% | 511.28% | $47.50 |
|
XGN
Exagen, Inc.
|
$17.3M | -$0.17 | 26.43% | -14.75% | $15.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XWEL
XWELL, Inc.
|
$0.46 | -- | $2.7M | -- | $0.00 | 0% | 0.08x |
|
FONR
FONAR Corp.
|
$18.56 | -- | $116.9M | 16.78x | $0.00 | 0% | 1.13x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$7.50 | $7.00 | $215M | -- | $0.00 | 0% | 45.63x |
|
PRPH
ProPhase Labs, Inc.
|
$0.45 | $13.80 | $1.9M | -- | $0.00 | 0% | 0.31x |
|
VCYT
Veracyte, Inc.
|
$42.10 | $47.50 | $3.3B | 110.91x | $0.00 | 0% | 6.76x |
|
XGN
Exagen, Inc.
|
$6.08 | $15.43 | $137.8M | -- | $0.00 | 0% | 1.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.710 | 3.29% | 2.57x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.343 | 11.39% | 3.63x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
XWELL, Inc. vs. Competitors
-
Which has Higher Returns XWEL or FONR?
FONAR Corp. has a net margin of -2.87% compared to XWELL, Inc.'s net margin of 10.25%. XWELL, Inc.'s return on equity of -224.93% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital XWELXWELL, Inc.17.32% -$0.26 $13M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About XWEL or FONR?
XWELL, Inc. has a consensus price target of --, signalling upside risk potential of 1419.1%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that XWELL, Inc. has higher upside potential than FONAR Corp., analysts believe XWELL, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings XWELXWELL, Inc.0 0 0 FONRFONAR Corp.0 0 0 -
Is XWEL or FONR More Risky?
XWELL, Inc. has a beta of 1.326, which suggesting that the stock is 32.585% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.
-
Which is a Better Dividend Stock XWEL or FONR?
XWELL, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XWEL or FONR?
XWELL, Inc. quarterly revenues are $7.3M, which are smaller than FONAR Corp. quarterly revenues of $26M. XWELL, Inc.'s net income of -$211K is lower than FONAR Corp.'s net income of $2.7M. Notably, XWELL, Inc.'s price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 16.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL, Inc. is 0.08x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XWELXWELL, Inc.0.08x -- $7.3M -$211K FONRFONAR Corp.1.13x 16.78x $26M $2.7M
-
Which has Higher Returns XWEL or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of -2.87% compared to XWELL, Inc.'s net margin of -4174.62%. XWELL, Inc.'s return on equity of -224.93% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital XWELXWELL, Inc.17.32% -$0.26 $13M IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About XWEL or IMDX?
XWELL, Inc. has a consensus price target of --, signalling upside risk potential of 1419.1%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could fall by -6.67%. Given that XWELL, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe XWELL, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XWELXWELL, Inc.0 0 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is XWEL or IMDX More Risky?
XWELL, Inc. has a beta of 1.326, which suggesting that the stock is 32.585% more volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.885%.
-
Which is a Better Dividend Stock XWEL or IMDX?
XWELL, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XWEL or IMDX?
XWELL, Inc. quarterly revenues are $7.3M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. XWELL, Inc.'s net income of -$211K is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, XWELL, Inc.'s price-to-earnings ratio is -- while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL, Inc. is 0.08x versus 45.63x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XWELXWELL, Inc.0.08x -- $7.3M -$211K IMDXInsight Molecular Diagnostics, Inc.45.63x -- $260K -$10.9M
-
Which has Higher Returns XWEL or PRPH?
ProPhase Labs, Inc. has a net margin of -2.87% compared to XWELL, Inc.'s net margin of -774.52%. XWELL, Inc.'s return on equity of -224.93% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital XWELXWELL, Inc.17.32% -$0.26 $13M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About XWEL or PRPH?
XWELL, Inc. has a consensus price target of --, signalling upside risk potential of 1419.1%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 30737.99%. Given that ProPhase Labs, Inc. has higher upside potential than XWELL, Inc., analysts believe ProPhase Labs, Inc. is more attractive than XWELL, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XWELXWELL, Inc.0 0 0 PRPHProPhase Labs, Inc.0 0 0 -
Is XWEL or PRPH More Risky?
XWELL, Inc. has a beta of 1.326, which suggesting that the stock is 32.585% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock XWEL or PRPH?
XWELL, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XWEL or PRPH?
XWELL, Inc. quarterly revenues are $7.3M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. XWELL, Inc.'s net income of -$211K is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, XWELL, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL, Inc. is 0.08x versus 0.31x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XWELXWELL, Inc.0.08x -- $7.3M -$211K PRPHProPhase Labs, Inc.0.31x -- $883K -$6.8M
-
Which has Higher Returns XWEL or VCYT?
Veracyte, Inc. has a net margin of -2.87% compared to XWELL, Inc.'s net margin of 14.51%. XWELL, Inc.'s return on equity of -224.93% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital XWELXWELL, Inc.17.32% -$0.26 $13M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About XWEL or VCYT?
XWELL, Inc. has a consensus price target of --, signalling upside risk potential of 1419.1%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 12.83%. Given that XWELL, Inc. has higher upside potential than Veracyte, Inc., analysts believe XWELL, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XWELXWELL, Inc.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is XWEL or VCYT More Risky?
XWELL, Inc. has a beta of 1.326, which suggesting that the stock is 32.585% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock XWEL or VCYT?
XWELL, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XWEL or VCYT?
XWELL, Inc. quarterly revenues are $7.3M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. XWELL, Inc.'s net income of -$211K is lower than Veracyte, Inc.'s net income of $19.1M. Notably, XWELL, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 110.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL, Inc. is 0.08x versus 6.76x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XWELXWELL, Inc.0.08x -- $7.3M -$211K VCYTVeracyte, Inc.6.76x 110.91x $131.9M $19.1M
-
Which has Higher Returns XWEL or XGN?
Exagen, Inc. has a net margin of -2.87% compared to XWELL, Inc.'s net margin of -41.1%. XWELL, Inc.'s return on equity of -224.93% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital XWELXWELL, Inc.17.32% -$0.26 $13M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About XWEL or XGN?
XWELL, Inc. has a consensus price target of --, signalling upside risk potential of 1419.1%. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 153.76%. Given that XWELL, Inc. has higher upside potential than Exagen, Inc., analysts believe XWELL, Inc. is more attractive than Exagen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XWELXWELL, Inc.0 0 0 XGNExagen, Inc.8 0 0 -
Is XWEL or XGN More Risky?
XWELL, Inc. has a beta of 1.326, which suggesting that the stock is 32.585% more volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.324%.
-
Which is a Better Dividend Stock XWEL or XGN?
XWELL, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XWEL or XGN?
XWELL, Inc. quarterly revenues are $7.3M, which are smaller than Exagen, Inc. quarterly revenues of $17.2M. XWELL, Inc.'s net income of -$211K is higher than Exagen, Inc.'s net income of -$7.1M. Notably, XWELL, Inc.'s price-to-earnings ratio is -- while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL, Inc. is 0.08x versus 1.94x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XWELXWELL, Inc.0.08x -- $7.3M -$211K XGNExagen, Inc.1.94x -- $17.2M -$7.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
